Share this article and save a life!
The mammogram that tells your future just got FDA approval.
In 2025, we crossed a remarkable threshold. The FDA authorized Clairity Breast, the first AI system that predicts your five-year breast cancer risk from a single standard mammogram.
No family history questionnaires.
No genetic testing.
Just the imaging data you’re already collecting.
Think about what this means:
📊 Every routine screening becomes a risk assessment
🎯 High-risk women get identified for enhanced screening
⏰ Prevention strategies start years before cancer develops
💡 Health equity improves (no literacy barriers from questionnaires)
The technology was validated on hundreds of thousands of mammograms. It doesn’t just detect existing cancer, it predicts future risk based on subtle tissue patterns invisible to human eyes.
Here’s the game changer:
We screen 40 million women annually for breast cancer. Until now, most received the same one-size-fits-all protocol. This AI enables truly personalized screening intervals, supplemental imaging decisions, and prevention conversations.
But here’s my concern:
Will insurance cover risk-based screening protocols? Will health systems invest in the infrastructure? Will radiologists embrace predictive, not just diagnostic, roles?
We have the technology to prevent thousands of late-stage diagnoses. The FDA opened the door. Now healthcare leaders must walk through it.
The future of cancer screening isn’t finding disease.
It’s preventing it from happening.
♻️ Repost if personalized cancer prevention should be standard care.
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
Jonathan Govette is a seasoned healthcare and technology executive with more than two decades of experience building, scaling, and advising digital health companies. He is the Co-Founder and CEO of Oatmeal Health, an AI-driven Lung Cancer Screening and Diagnostics company focused on expanding access to early detection for underrepresented populations, particularly patients served by Federally Qualified Health Centers and value-based health plans.
With a background in engineering, product development, and strategic partnerships, Jonathan has founded and led multiple health technology ventures across clinical care delivery, regulated medical software, and AI-enabled diagnostics. His work sits at the intersection of medicine, technology, and health equity, with a consistent focus on translating complex clinical problems into scalable, real-world solutions.
Jonathan has spent much of his professional life dedicated to improving outcomes for marginalized and underserved communities. He has designed and implemented frameworks that align clinical quality, reimbursement, and technology to sustainably advance health equity at scale. This mission is deeply personal and informs his leadership philosophy and long-term vision for healthcare transformation.
In addition to his operating experience, Jonathan is an author and long-time writer in the healthcare domain, with over 20 years of published work covering digital health, medical innovation, and healthcare systems. He is a frequent mentor to early-stage founders and regularly advises startups on product strategy, partnerships, and go-to-market execution in regulated healthcare environments.
Before entering industry full-time, Jonathan nearly pursued a career in medicine with an early path toward cardiothoracic surgery, an experience that continues to shape his clinical perspective and respect for frontline care delivery.
CEO | Oatmeal Health | AI Lung Cancer Startup | Engineer | Writer | Almost Became a Doctor (Cardiac Thoracic Surgeon) | 3x Health Tech Founder | Startup Mentor | Follow to share what I’ve learned along the way.
